ライフサイエンスコーパス: enrollment

1 for free or reduced-price lunch, and school enrollment).

2 roids or hospitalization] in the year before enrollment).

3 nt) or chronic (diagnosis >3 months prior to enrollment).

4 indicated (18)F-fluciclovine PET/CT prior to enrollment.

5 bilobectomy for malignancy were eligible for enrollment.

6 2.6%) were scraped and cultured 6 days after enrollment.

7 s had impaired neurocognitive performance at enrollment.

8 % of the beneficiaries died within 7 days of enrollment.

9 ed for a second COPDGene visit 5 years after enrollment.

10 were linked to the participant residence at enrollment.

11 s with a diagnosis of BCNS were eligible for enrollment.

12 ontinuation of bendamustine and cessation of enrollment.

13 study and completed a diet questionnaire at enrollment.

14 e trial ended before planned because of slow enrollment.

15 ained from study participants at day 6 after enrollment.

16 ollowed 1, 2, or 3 years at the end of study enrollment.

17 dispersant exposure and symptoms present at enrollment.

18 Alcon Research, Fort Worth, Texas, USA) pre-enrollment.

19 sease (MRD) assessments 9 months after study enrollment.

20 oncologic condition 1 month to 1 year before enrollment.

21 by genetic counselors 12 to 14 months after enrollment.

22 rs who did not have functional impairment at enrollment.

23 pletely encompassed by time periods prior to enrollment.

24 y (both predominantly white individuals), at enrollment.

25 ed lifetime use of 50 specific pesticides at enrollment.

26 nts regardless of blood eosinophil counts at enrollment.

27 Few (5%) reported any cancer prior to enrollment.

28 e previous trials and factors measured at re-enrollment.

29 llment to 0.53, 0.19, and 0.76 after hospice enrollment.

30 ospital admission rate in the 24 hours after enrollment.

31 Informed consent was obtained prior to enrollment.

32 nformation that has been self-reported after enrollment.

33 ment or recurrent malignancy at 1 year after enrollment.

34 and had experienced an MI <10 y before study enrollment.

35 cute medical service utilization after their enrollment.

36 me episodes (n = 4) in the 2 years preceding enrollment.

37 y outcome was partner testing within 3 mo of enrollment.

38 standardized ultrasound examination at their enrollment.

39 tion on antibiotic prescribing guidelines on enrollment.

40 ined at enrollment and from one visit before enrollment.

41 alignancies; 3 had known risk factors before enrollment.

42 ault MVC involvement over the 5 years before enrollment.

43 were receiving statin therapy at the time of enrollment.

44 follow-up at 1, 3, 6, 9, and 12 months after enrollment.

45 ) were identified as being employed at study enrollment.

46 ated food-frequency questionnaire 10 d after enrollment.

47 pondent-driven sampling targeted cis-MSM for enrollment.

48 medical service utilization before and after enrollment.

49 Tc-methylene diphosphonate bone scan) before enrollment.

50 ary Angiography and Angioplasty Registry for enrollment.

51 /=48%) >/=4 days poststent were eligible for enrollment.

52 ancer Index Composite (EPIC) 36 months after enrollment.

53 sent was obtained from all subjects prior to enrollment.

54 e, and combination antiretroviral therapy at enrollment.

55 prescription medications, were eligible for enrollment.

56 sponse was related to attributes measured at enrollment.

57 of the OSRC, as well as at the time of study enrollment, 1-3 y after the spill.

58 cies with known birth outcomes followed from enrollment (11-13 wk) and for </=6 research visits throu

59 provement from the first to last quartile of enrollment (11.3% [quartile 1]) to 7.8% [quartile 2], 6.

60 e patients in the control group had shock at enrollment (14 vs 3 patients).

61 In the year after study enrollment, 1661 patients died (15.9% by life-table anal

62 ide use and other factors was ascertained at enrollment (1993-1997) and updated with a follow-up ques

63 through linkage with cancer registries from enrollment (2005-2007) to 2011.

64 Of the 611 patients consented to study enrollment, 380 met the inclusion criteria and were rand

65 At enrollment, 473 boys had serum dioxin-like compounds and

66 systemic therapy) (77% female; median age at enrollment, 48 [interquartile range, 36-56] years).

67 Patients with TTNtv were younger at enrollment (49.0 years vs. 54.1 years; p = 0.002) and ha

68 at the time of enrollment (mean [SD] age at enrollment, 55.6 [10.9] years).

69 Among the 607 participants (mean [SD] age at enrollment, 57.5 [10.9] years), 334 (55.0%) were men and

70 ed African Americans' probability of college enrollment 7-9 y later.

71 es; 60.2% women and 39.8% men; median age at enrollment, 70 years [range, 42-90 years]), the 3-year c

72 entional enrichment strategies that restrict enrollment according to the baseline risk of death.

73 higher among those with longer residence at enrollment address and those who spent > 1 hr/day outdoo

74 rs or who had lived 5 or more years at their enrollment address, the HR was 1.68 (95% CI: 1.28, 2.22)

75 s reported during the OSRC work and at study enrollment, adjusting for potential confounders includin

76 total of 560 randomized participants (median enrollment age, 8.2 years; interquartile range [IQR], 5.

77 academic or nonacademic), training hospital, enrollment age, sex, and test date.

78 ted using logistic regression, adjusting for enrollment age, state, smoking pack-years, and education

79 After adjusting for year of enrollment, age, etiology, and disease severity, whereas

80 were matched with the case group for time of enrollment, age, sex, history of coronary artery disease

81 ption of the oldest subject (15 years old at enrollment), all subjects remained off ERT with normaliz

82 t due to protocol complexity and low patient enrollment, among other factors.

83 Of 378 cancer diagnoses between enrollment and 2010 identified through self-report and v

84 013 was analyzed, including 2632 patients on enrollment and 2452 reevaluated after 12 months of ART c

85 performed on 486 cases and 442 controls upon enrollment and 365 cases at follow-up.

86 ic questionnaires were administered at study enrollment and at 5-year follow-up.

87 m Short Form Survey (SF-36) were obtained at enrollment and at 6 months (or prior, in the event of ea

88 o were 70 years or older without dementia at enrollment and at least one annual follow-up was studied

89 Enrollment and complete health insurance claims of 9.7 m

90 ed nationwide Swedish registries for patient enrollment and data collection.

91 onal Death Index identified suicides between enrollment and December 31, 2010 (follow-up 3-25 years).

92 nasal swabs for viral PCR were performed at enrollment and during convalescence.

93 Enrollment and follow-up stools were tested by quantitat

94 y and intraocular pressure, were obtained at enrollment and from one visit before enrollment.

95 the design of methods that facilitate rapid enrollment and interpretation of clinical trials by aggr

96 10-2016), with serum suPAR level measured at enrollment and longitudinal eGFR measured prospectively.

97 ive interaction between malaria infection at enrollment and low MUAC within studies conducted in Afri

98 Early prenatal enrollment and micronutrient use during the first trimes

99 on analyses to longitudinal health insurance enrollment and nationwide MarketScan insurance claims da

100 Samples were collected at patient enrollment and not during acute symptom flares.

101 After enrollment and randomization, 31 volunteers received pro

102 g Enterobacteriaceae (one that has completed enrollment and the other in late protocol development) w

103 heating and cooking practices for both their enrollment and their longest adult residence.

104 ve exacerbations during the 12 months before enrollment and then documented prospective exacerbations

105 Specimens obtained at enrollment and then quarterly for 12 months and at sick

106 ion, health, and hygiene education (NHHE) at enrollment and throughout the 12 mo.

107 Stools were collected at enrollment and, for cases, after a 5-mo nutritional inte

108 ating more recent infection) from treatment (enrollment) and 6-month follow-up visits in 77 women pre

109 assessed, 1030 met eligibility criteria for enrollment, and 446 declined participation.

110 nd glycated hemoglobin A1c [HbA1c] level) at enrollment, and cases were tested again after receipt of

111 Serum suPAR level was measured at enrollment, and eGFR was measured every 2 months in the

112 :1:1) to receive IPV at 5 months (arm A), at enrollment (arm B), or no vaccine (arm C).

113 ere conducted with RBC transfusion on day of enrollment as the outcome and admission to an ICU with a

114 timulating factor, and C-reactive protein at enrollment as well as after 7-14 days of admission.

115 immune modulation and anti-inflammatory cell enrollment as well as prevents oxidative stress and cyto

116 ovide retrospective addresses prior to study enrollment, as well as the concordance with existing pro

117 itially of 5,362 individuals, followed since enrollment at birth in March 1946.

118 ponding contralateral teeth were examined at enrollment; at day 0, after reinstitution of gingival/mu

119 ents with >/=1 year of continuous MarketScan enrollment before and after implant and without a previo

120 Registry enrollment began in 2008, and data were abstracted in Se

121 Enrollment began in 2012 and is planned to continue in m

122 Enrollment began in April 2011 and follow-up concluded i

123 ADAGES enrollment began in January 2003 and ended in July 2006;

124 Enrollment began May 2013 and follow-up ended July 2015.

125 Enrollment began October 19, 2005; follow-up data were c

126 ons of baseline clinical characteristics and enrollment biomarker levels with survival.

127 e risk prediction to inform study design and enrollment, but available risk estimates are limited.

128 el could be rising or falling at the time of enrollment, but had to be higher than 4.0 ng/mL.

129 The distribution of enrollment by age in phase III non-ST-segment-elevation

130 Nadir and enrollment CD4 counts, activated T-cells, and time on AR

131 T group, 886 participants started therapy at enrollment (CD4+ count, 350 to 550 cells per cubic milli

132 ng women with malaria infection at antenatal enrollment compared to 7.7% among uninfected women (adju

133 with both malaria infection and low MUAC at enrollment compared to 8.4% among uninfected women with

134 mid-upper arm circumference (MUAC <23 cm) at enrollment compared to 9.5% among women with MUAC >/= 23

135 iated with bilateral cataract surgery before enrollment compared with baseline bilateral phakia (HR,

136 ohol consumption (last drink <10 days before enrollment) compared to those without recent drinking.

137 h study, including recruitment, consent, and enrollment, conducted entirely remotely by smartphone.

138 ing patient coaching (intervention group) or enrollment (control).

139 atient increase (up to 100 patients) in site enrollment correlated with lower likelihood of protocol

140 y ICU, 52% of patients (n = 48) did not meet enrollment criteria for any studied randomized controlle

141 maximize generalizability of results, trial enrollment criteria should strive for inclusiveness.

142 duration, as this factor has been used as an enrollment criterion in clinical trials.

143 We used cross-sectional enrollment data from African-American women enrolled in

144 ing the Medicare Standard Analytic Files and Enrollment Database together with VA administrative clai

145 Hospice enrollment, days enrolled in hospice, in-home death, and

146 kg/m2), the predicted probability of hospice enrollment decreased by 15.2 percentage points (CI, -19.

147 kg/m2, the predicted probability of hospice enrollment decreased by 6.7 percentage points (CI, -9.3

148 Age at transplant and enrollment, dialysis duration, and previous disease were

149 At enrollment, DM prevalence was significantly higher among

150 The median hospice enrollment duration was 20 days.

151 onal Death Registry, and the bundled-payment enrollment file.

152 Enrollment, fluid delivery, and data collection were per

153 d pneumonia (n = 182) were obtained at study enrollment (following antibiotic treatment); patient dem

154 Target enrollment for each study was 285 patients.

155 ve studies of disease progression and during enrollment for future clinical trials.

156 stage 0 to III and with continuous insurance enrollment from at least 1 month prior to the month of d

157 nfliximab or adalimumab) were included, with enrollment from June 1, 2013, to June 1, 2015.

158 At the time of registry enrollment, GenTAC study participants are asked to compl

159 ere measured in maternal peripheral blood at enrollment, gestational week 30-32, and delivery, and in

160 omen (N = 36,794) ages 50 to 79 years at WHI enrollment had their body weights measured and body mass

161 At enrollment, HPV infection was detected in 54% of HIV-neg

162 linical information to be collected at study enrollment, important aspects related to patient managem

163 e, demographics, and reproductive history at enrollment in 1993-1997 and in 5-y follow-up interviews.

164 Five patients (6%) died after initial enrollment in 2008.

165 rsons at risk for Alzheimer disease (AD) for enrollment in AD prevention trials.

166 the patients assessed were not eligible for enrollment in any of 15 major randomized controlled tria

167 s associated with increased risk of ICH were enrollment in Asia or Latin America, older age, prior st

168 nts in these treatment options combined with enrollment in clinical trials are essential to improve t

169 Active enrollment in clinical trials whenever possible was endo

170 g elderly patients with OPSCC, their limited enrollment in clinical trials, and the aging US populati

171 trials are too restrictive and limit patient enrollment in clinical trials.

172 unresolved challenge that restricts patient enrollment in gene therapy clinical trials using recombi

173 ar care provider, increasing access to care, enrollment in health insurance, and higher education.

174 inal 30 days of life, enrollment in hospice, enrollment in hospice during the final 3 days of life, a

175 hospice during the final 3 days of life, and enrollment in hospice while not hospitalized.

176 ing procedures in the final 30 days of life, enrollment in hospice, enrollment in hospice during the

177 tients between 2005 and 2009 with continuous enrollment in Medicare Parts A & B (n = 24 581) to exami

178 listed between 2005 and 2013 with continuous enrollment in Medicare parts A and B (n = 53 810) to exa

179 fee-for-service will become less viable, and enrollment in new payment models will be unavoidable.

180 ting for maternal education, race/ethnicity, enrollment in public pre-Kindergarten, and gestational a

181 nce of amyloid has become a prerequisite for enrollment in several secondary prevention trials for AD

182 Enrollment in the experimental group was stopped when th

183 f 6 months each, starting at the time of the enrollment in the intervention.

184 47.4% and 28.8% started their first hospice enrollment in the last 7 and 3 days of life, respectivel

185 out an established diagnosis of ASCVD before enrollment in the registry by use of the SAFEHEART risk

186 children who were 5-8 years of age at study enrollment in the Southern California Children's Health

187 ong 98015 participants, the mean (SD) age at enrollment in the study was 48.3 (9.8) years, 97.0% were

188 nt was obtained from all participants before enrollment in the study.

189 At 31 months, enrollment in the trial was stopped because of the resul

190 Enrollment in the TTrials began June 24, 2010; the final

191 o improve the outcome for patients and their enrollment in therapeutic trials.

192 100000 beneficiary-years of fee-for-service enrollment, in-hospital mortality, 30-day stroke or deat

193 At enrollment, infants were examined for AD and screened fo

194 primary outcomes were feasibility (rates of enrollment, intervention receipt, 3- and 6-mo follow-up)

195 Enrollment interviews between 2011 and 2013 collected in

196 ailed Gulf Long-term Follow-up ( GuLF) Study enrollment interviews, we determined potential exposure

197 at the earliest stage of HIV-1 infection for enrollment into subsequent studies of cellular and viral

198 stimulating activities within 1 year before enrollment into the study.

199 of the following occurring within 7 days of enrollment: intravenous rehydration, hospitalization, su

200 te medical service utilization after hospice enrollment is limited.

201 When information collected after enrollment is through interview or exam, attrition leads

202 individually matched on age group, sex, and enrollment length in months to 5 persons without a giard

203 es, including current health status at study enrollment (</=7 days from illness onset) and current ac

204 Encouraging earlier and increased hospice enrollment may improve EOL experiences for patients with

205 ndergone intracranial imaging at the time of enrollment (mean [SD] age at enrollment, 55.6 [10.9] yea

206 ring nonadherence rates eight weeks prior to enrollment, median appointment adherence after using the

207 After enrollment, mixed infections (multiplicity of infection,

208 gebase development, and patient matching and enrollment models, which are critical for translating ou

209 When adjusted for age, enrollment month, and detection of other respiratory vir

210 Enrollment occurred between May 2010 and August 2014; th

211 ts had a median (interquartile range) age at enrollment of 2.6 (0.4-9.1) years; 358 (49.9%) were male

212 After the planned enrollment of 252 patients, the protocol was amended to

213 ecified stopping criteria were met after the enrollment of 90 of 114 patients.

214 rbidity and may allow for identification and enrollment of high-risk subgroups for future studies.

215 To increase the rate of enrollment of HIV PCR-positive children, HIV-exposed neo

216 pneumonia should be cautioned, but targeted enrollment of marginal patients with pneumonia could enr

217 istory of the disease, progress will rely on enrollment of patients into clinical trials and molecula

218 Inclusion criteria allowed enrollment of patients with recent myocardial infarction

219 of each component of the CIS, non-concurrent enrollment of the CIS+ group, and exclusion of many pati

220 erculosis disease developed >/=15 days after enrollment of the index patient.

221 benefits associated with lowering the age of enrollment on oncology clinical trials.

222 clude controls with respiratory illness from enrollment or analyses.

223 zed as acute (diagnosis </=3 months prior to enrollment) or chronic (diagnosis >3 months prior to enr

224 followed until end of 2006, end of Medicaid enrollment, or occurrence of study outcome.

225 premature menopause (29.3%) were younger at enrollment (P < 0.001) and used hormone replacement ther

226 At enrollment, patients were 68 +/- 12 years old (median +/

227 ity HCV incidence trends, HCV rates by study enrollment period (1985-2011), and temporal trends in ex

228 ared to decrease during the relatively short enrollment period of the clinical trial.

229 Throughout the enrollment period, 219 endoscopists (74.5%) increased th

230 At the time of enrollment, plasma norepinephrine, serum NT-proBNP, and

231 baseline clinical evaluation and imaging at enrollment (positron emission tomography and 2-dimension

232 In the year prior to enrollment, PPI+ group lost more CD4 cells than PPI- (-1

233 After adjustment, increasing site enrollment predicted higher risk of persistent dyspnea a

234 ctions confirmed by microscopy and/or PCR at enrollment ranged from 91% (95% confidence interval [CI]

235 The overall enrollment rate was 46% (4505 of 9820).

236 A total of 145 patients enrolled (77% enrollment rate), and 126 remained eligible.

237 We enrolled 145 patients (79.7% enrollment rate), and received surveys from 131 patients

238 Serum OCs were measured in the enrollment samples using high-resolution mass spectromet

239 CI, 76%, 90%) and 77% (95% CI, 67%, 86%) at enrollment, second and third ANC visits respectively but

240 Enrollment spanned from December 23, 2009, to April 23,

241 Enrollment started May 24, 2010, and the last patient st

242 y on functional outcome measures for patient enrollment, stratification, and evaluation.

243 ncrease was primarily driven by late hospice enrollment that occurred in the last 7 days of life.

244 At enrollment, the detection of enteroaggregative Escherich

245 Thirteen months after enrollment, the independent data and safety monitoring b

246 During enrollment, the oximeters were revised to correct a cali

247 After 3 months of enrollment, the study was closed because of the futility

248 gent with a falling PSA level at the time of enrollment; this therapy was continued in this cohort.

249 Among patients who tested positive at enrollment, those with positive 6-day cultures had signi

250 e incidence of HF hospitalization from study enrollment through 2014.

251 patients without HE (1:1, controls) for sex, enrollment time, end point time, follow-up period, and a

252 XTRACTION: Baseline patient characteristics, enrollment time, methodology of cooling, target temperat

253 sed from 2.56, 0.87, and 1.17 before hospice enrollment to 0.53, 0.19, and 0.76 after hospice enrollm

254 as measured by a change in FACT-G score from enrollment to 12 weeks, was significantly higher in pati

255 average, increased by 9.2 points from trial enrollment to 6 months (95% confidence interval [CI]: 4.

256 Children were visited weekly from enrollment to age 9 months; the mother reported morbidit

257 risk variables were collected at the time of enrollment to enable prognostic model development.

258 t tissue ultrasound performed at the time of enrollment to exclude abscess.

259 Our computations suggest that restricting enrollment to patients in whom ECCO2R allows driving pre

260 Serum samples were obtained at enrollment to quantify the concentrations and neutralizi

261 injury (between the ages of 3 and 7 years at enrollment) to an average of 6.7 years after injury, wit

262 Enrollment took place from July 1, 2008, to July 31, 201

263 ents for delirium and coma twice daily after enrollment using the Confusion Assessment Method for the

264 In the cohort, 47.1% enrolled in QHPs, and enrollment varied significantly based on demographic and

265 were male, and the mean (SD) patient age at enrollment was 11.9 (3.5) years.

266 Mean IOP at enrollment was 15.4 +/- 3.6 mm Hg in right eyes and 15.4

267 e mean left ventricular ejection fraction at enrollment was 28+/-9%.

268 Results Planned enrollment was 356 patients; accrual ceased at 272 becau

269 kg/m2, the predicted probability of hospice enrollment was 38.3% (95% CI, 36.5% to 40.2%), hospice d

270 the second HF hospital discharge and hospice enrollment was 45.

271 The mean (SD) age at enrollment was 49 (13) years, 104 participants (43.3%) w

272 Median time from diagnosis to enrollment was 5 weeks, and all men were enrolled with w

273 The mean age at enrollment was 68.6+/-9.6 years.

274 Median age at enrollment was 75.6 years (range, 62.6-87.8 years); 97%

275 1992 to 2009, the mean [SD] age at the last enrollment was 82.2 [7.7] years.

276 Hyperglycemia, based on the FCG level, at enrollment was associated with tuberculosis treatment fa

277 Enrollment was completed in 2013; follow-up is ongoing.

278 Enrollment was from February 2014 to August 2015 with fo

279 Enrollment was from July 2001 to August 2003.

280 Higher site enrollment was independently associated with lower risk

281 First enrollment was March 2011, last follow-up was February 2

282 4(+), and regulatory T-lymphocyte subsets at enrollment was not associated with clinical response.

283 ault MVC involvement over the 5 years before enrollment was obtained from state records.

284 Chemotherapy use before enrollment was optional.

285 95% CI: -0.14, -0.06), whereas the number at enrollment was positively associated with the change in

286 126 of 215 planned patients were randomized; enrollment was stopped early following release of the SE

287 ives with no history of breast cancer before enrollment, we examined breast cancer risk in relation t

288 At enrollment, we measured frailty using the Clinical Frail

289 and factors associated with time to hospice enrollment were evaluated.

290 dioverter-defibrillator at the time of trial enrollment were excluded.

291 rategy) trial with planned angiography after enrollment were included.

292 ngly associated with shorter time to hospice enrollment were older age (adjusted hazard ratio, 1.77;

293 ime under observation and gestational age at enrollment, were used to calculate hazard ratios.

294 ed from 2 to 5 years, depending on timing of enrollment (which spanned 2 years), treatment group to w

295 Women with malaria at enrollment who received >/=2 doses vs 0-1 had 76% lower

296 signment in the original trial, and month of enrollment with a subset of cases sampled longitudinally

297 istory of TBI at least 4 months before study enrollment with either objective cognitive deficits or s

298 The association of patent infections at enrollment with low birth weight suggests the importance

299 petency was assessed throughout 24 months of enrollment with multiple-choice question (MCQ) examinati

300 Medicare and Medicaid Services for the 2016 enrollment year.